Janus Henderson Group PLC reduced its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 21.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,993,206 shares of the medical research company’s stock after selling 1,107,082 shares during the quarter. Janus Henderson Group PLC owned about 4.18% of NeoGenomics worth $87,611,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently made changes to their positions in the business. NEXT Financial Group Inc grew its position in shares of NeoGenomics by 200.0% in the 2nd quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 1,800 shares during the period. Winslow Evans & Crocker Inc. acquired a new position in NeoGenomics during the 2nd quarter worth approximately $92,000. Oregon Public Employees Retirement Fund acquired a new position in NeoGenomics during the 1st quarter worth approximately $132,000. Mark Sheptoff Financial Planning LLC acquired a new position in NeoGenomics during the 1st quarter worth approximately $141,000. Finally, South Dakota Investment Council acquired a new position in NeoGenomics during the 1st quarter worth approximately $149,000. 79.00% of the stock is owned by hedge funds and other institutional investors.
NEO has been the subject of a number of recent research reports. BidaskClub raised NeoGenomics from a “hold” rating to a “buy” rating in a research report on Friday, July 19th. Needham & Company LLC set a $27.00 price target on NeoGenomics and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Benchmark set a $27.00 price target on NeoGenomics and gave the stock a “buy” rating in a research report on Wednesday, July 31st. ValuEngine downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Raymond James increased their price objective on NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $23.78.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, July 30th. The medical research company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. The business had revenue of $101.71 million for the quarter, compared to analysts’ expectations of $97.32 million. NeoGenomics had a return on equity of 4.97% and a net margin of 0.57%. The firm’s revenue for the quarter was up 50.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.05 EPS. Equities analysts anticipate that NeoGenomics, Inc. will post 0.19 earnings per share for the current fiscal year.
In other news, Director Steven C. Jones sold 40,737 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $25.02, for a total transaction of $1,019,239.74. Following the sale, the director now directly owns 245,234 shares of the company’s stock, valued at approximately $6,135,754.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider William Bonello sold 17,000 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $24.83, for a total value of $422,110.00. Following the completion of the sale, the insider now directly owns 23,735 shares in the company, valued at $589,340.05. The disclosure for this sale can be found here. Over the last three months, insiders have sold 239,676 shares of company stock worth $5,975,330. 8.80% of the stock is currently owned by insiders.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: Do equity income investments outperform growth and income investments?
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.